La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Y-mAbs Therapeutics Gestione
Gestione criteri di controllo 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Mike Rossi
Amministratore delegato
US$3.1m
Compenso totale
Percentuale dello stipendio del CEO | 3.5% |
Mandato del CEO | less than a year |
Proprietà del CEO | n/a |
Durata media del management | 3.4yrs |
Durata media del Consiglio di amministrazione | 6.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Aug 12We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Jul 15Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
Jun 02Y-mAbs: There's A Ceiling Here Somewhere
May 09We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Jul 16Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts
May 13Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%
Apr 17Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
Mar 22We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully
Dec 13Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
Aug 13Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers
Jul 12Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 30Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?
May 12Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$25m |
Mar 31 2024 | n/a | n/a | -US$22m |
Dec 31 2023 | US$3m | US$110k | -US$21m |
Compensazione vs Mercato: La retribuzione totale di Mike ($USD 3.11M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.44M ).
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Mike con le performance aziendali.
AMMINISTRATORE DELEGATO
Mike Rossi (53 yo)
less than a year
Mandato
US$3,110,553
Compensazione
Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO, President & Director | less than a year | US$3.11m | Nessun dato | |
Founder | 9.3yrs | US$2.45m | 0.75% $ 4.2m | |
Senior VP & Chief Commercial Officer | 2.6yrs | US$887.28k | 0.0095% $ 53.1k | |
CFO & Treasurer | less than a year | Nessun dato | Nessun dato | |
Senior VP & COO | 6.8yrs | Nessun dato | 0.013% $ 74.1k | |
Senior VP & CTO | 8.6yrs | Nessun dato | 0.12% $ 644.4k | |
Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
Senior VP & Chief Medical Officer | 4.2yrs | US$724.92k | 0.019% $ 106.0k | |
Chief Development Officer | less than a year | Nessun dato | Nessun dato |
3.4yrs
Durata media
54.5yo
Età media
Gestione esperta: Il team dirigenziale di YMAB è considerato esperto (durata media dell'incarico 3.4 anni).
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO, President & Director | less than a year | US$3.11m | Nessun dato | |
Founder | 9.3yrs | US$2.45m | 0.75% $ 4.2m | |
Independent Chairman of the Board | 6.8yrs | US$184.31k | 0.063% $ 351.1k | |
Independent Director | 6.7yrs | US$180.56k | 0.0052% $ 29.1k | |
Director | less than a year | Nessun dato | 0% $ 0 | |
Independent Director | 8.9yrs | US$158.06k | 0.0052% $ 29.1k | |
Independent Director | 6.8yrs | US$158.06k | 0.0052% $ 29.1k | |
Independent Director | 4.2yrs | US$168.06k | 0.0052% $ 29.1k |
6.7yrs
Durata media
56yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di YMAB sono considerati esperti (durata media dell'incarico 6.7 anni).